Floatz logo

Vofatamab

FGFR3

Fusion Pharmaceuticals Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the FGFR3 cohort.

Asset / SponsorPhaseRating
[225Ac]-FPI-1966
Fusion Pharmaceuticals Inc.
Phase 1/2CCC
[111in]-fpi-1967
Fusion Pharmaceuticals Inc.
Phase 1/2CCC

Same molecule, other indications

Vofatamab is also rated in:

Susceptible FGFR3 Genetic AlterationsDormant
CCC
Indicative ·
48 / 100
View asset →
FGFR3 OverexpressionDormant
CCC
Indicative ·
48 / 100
View asset →
FGFR3 ReceptorDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →